Mayne Pharma Appoints Executive Vice President at Metrics Contract Services

Published: Jul 19, 2017

July 19, 2017, Greenville, N.C: Mayne Pharma has appointed Kimberly McClintock as executive vice president at Metrics Contract Services, the company’s contract pharmaceutical development and manufacturing division.

McClintock brings to Metrics Contract Services extensive experience in leading and growing pharmaceutical CDMOs. Her areas of industry expertise include research and development, project management, sales and business development.

John Ross, president of Mayne Pharma USA and former EVP at Metrics Contract Services, said, “Kim McClintock joins the organization at an exciting time when it is poised to open in early 2018 a new $80-million solid oral dose manufacturing facility in Greenville, N.C. Kim is a dynamic leader with an engaging and inclusive management style and is well positioned to guide Metrics Contract Services through this next phase of growth.”

Prior to joining Metrics Contract Services, McClintock served as senior director and business team lead for Alcami Corp., where she led the drug product development, manufacturing and laboratory testing services business unit. She holds a master’s degree in business administration and management from the University of North Carolina at Greensboro, and a bachelor’s degree in chemistry from N.C. State University.

As a full-service CDMO, Metrics Contract Services has delivered proven scientific and operational excellence for oral dosage forms to clients worldwide for more than 20 years. Its areas of expertise include quality pharmaceutical formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial-scale manufacturing.

Metrics Contract Services’ technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioavailability, for which the organization offers an impressive proprietary portfolio of advanced delivery methods.

Mayne Pharma is investing $80 million in a new 126,000-square-foot, oral-dose commercial manufacturing facility that will quadruple the company’s U.S. manufacturing capacity. The company also will dedicate 10+ new manufacturing suites and analytical laboratories for pre-commercial activities, more than doubling current development and clinical capacity.

Once construction is complete, Metrics Contract Services will offer a more comprehensive “concept to commercialization” solution for clients — providing larger scale and increased capabilities for seamless scale-up in one contiguous location.

One highlight of the expansion includes commercial-scale manufacturing capability with solvent-based, fluid-bed processing and film coating — a first for Mayne Pharma operations in the United States. To learn more about Metrics Contract Services and its capabilities, visit online at www.metricscontractservices.com (http://www.metricscontractservices.com) .

Back to news